. Author manuscript; available in PMC: 2013 Jul 31.

Published in final edited form as: J Hepatol. 2010 Dec 15;55(2):315–321. doi: 10.1016/j.jhep.2010.11.020

Table 5.

Mean MAP at end of treatment (EOT) vs baseline for terlipressin and placebo.

Treatment	n	Baseline	EOT	Change from baseline
Treatment	n	Mean (SD)	Mean (SD)	Mean change^* (SE)	p vs. baseline	Difference (SE)	p vs. placebo
Terlipressin	56	75.5 (11.4)	77.9 (11.2)	+1.8 (1.8)	0.333	6.2 (2.5)	0.017

Placebo	55	77.2 (13.7)	73.5 (11.4)	−4.4 (1.9)	0.020	-	-

Least squares mean.

Analysis using last observation carried forward. SD: standard deviation, SE: standard error, difference = terlipressin minus placebo.